Persistence and clearance of human papillomavirus infection: a prospective cohort study

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 6, 2008, Pages 617.e1-617.e7

  Rosa, Maria Inês ^a,c   Fachel, Jandira M G ^a   Rosa, Daniela D ^b   Medeiros, Lidia R ^a   Igansi, Cristine N ^a   Bozzetti, Mary C ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL MOINHOS DE VENTO   (Brazil)

^c UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

cervix cancer; gynecological infections; human papillomavirus clearance; human papillomavirus infection; risk factors

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIXED INFECTION; MORBIDITY; NEGRO; PAPANICOLAOU TEST; PRIORITY JOURNAL; SEXUAL INTERCOURSE; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; WART VIRUS;

EID: 57149130261     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.06.033     Document Type: Article

References (53)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Ferenczy A., and Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3 (2002) 11-16
3. American Cancer Society. Cancer facts and figures 2007 (2007), American Cancer Society, Atlanta (GA)
4. INCA. Estimativa 2006-incidência de câncer no Brasil (2006), Instituto Nacional do Câncer, Rio de Janeiro, Brazil
5. Ho G.Y., Bierman R., Beardsley L., Chang C.J., and Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
6. Franco E.L., Villa L.L., Sobrinho J.P., et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180 (1999) 1415-1423
7. Hildesheim A., Herrero R., Castle P.E., et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84 (2001) 1219-1226
8. Munoz N., Franceschi S., Bosetti C., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359 (2002) 1093-1101
9. Castle P.E., and Giuliano A.R. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr (2003) 2934
10. Goodman M.T., Kiviat N., McDuffie K., et al. The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii. Cancer Epidemiol Biomarkers Prev 7 (1998) 537-544
11. Haverkos H.W. Multifactorial etiology of cervical cancer: a hypothesis. Med Gen Med 7 (2005) 57
12. Misra J.S., Das V., Srivastava A.N., and Singh U. Role of different etiological factors in progression of cervical intraepithelial neoplasia. Diagn Cytopathol 34 (2006) 682-685
13. Berrington A., Jha P., Peto J., Green J., and Hermon C. Oral contraceptives and cervical cancer. Lancet 360 (2002) 410
14. Schlecht N.F., Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 (2001) 3106-3114
15. Hildesheim A., and Wang S.S. Host and viral genetics and risk of cervical cancer: a review. Virus Res 89 (2002) 229-240
16. Bauer H.M., Hildesheim A., Schiffman M.H., et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis 20 (1993) 274-278
17. Coutlee F., Gravitt P., Kornegay J., et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 40 (2002) 902-907
18. Griffais R., and Thibon M. Detection of Chlamydia trachomatis by the polymerase chain reaction. Res Microbiol 140 (1989) 139-141
19. Pannekoek Y., Westenberg S.M., de Vries J., et al. PCR assessment of Chlamydia trachomatis infection of semen specimens processed for artificial insemination. J Clin Microbiol 38 (2000) 3763-3767
20. Hamilton L.C. Interpreting multinomial logistic regression. Stata Tech Bull 13 (1993) 24-28
21. Clifford G.M., Gallus S., Herrero R., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
22. Lorenzato F., Ho L., Terry G., et al. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int J Gynecol Cancer 10 (2000) 143-150
23. Rabelo-Santos S.H., Zeferino L., et al. Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiania, Brazil. Mem Inst Oswaldo Cruz 98 (2003) 181-184
24. Cavalcanti S.M., Zardo L.G., Passos M.R., and Oliveira L.H. Epidemiological aspects of human papillomavirus infection and cervical cancer in Brazil. J Infect 40 (2000) 80-87
25. Noronha V., Mello W., Villa L., et al. [Human papillomavirus associated with uterine cervix lesions]. Rev Soc Bras Med Trop 32 (1999) 235-240
26. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87 (1995) 796-802
27. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
28. Woodman C.B., Collins S., Winter H., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 (2001) 1831-1836
29. Dalstein V., Riethmuller D., Pretet J.L., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 106 (2003) 396-403
30. Liaw K.L., Hildesheim A., Burk R.D., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 (2001) 8-15
31. Molano M., Van den Brule A., Plummer M., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158 (2003) 486-494
32. Syrjanen S., Shabalova I.P., Petrovichev N., et al. Clearance of high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States of the former Soviet Union (the NIS cohort study). Eur J Obstet Gynecol Reprod Biol 119 (2005) 219-227
33. Sellors J.W., Karwalajtys T.L., Kaczorowski J., et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168 (2003) 421-425
34. Freeman J., and Hutchison G.B. Prevalence, incidence and duration. Am J Epidemiol 112 (1980) 707-723
35. Greenberg J., Magder L., and Aral S. Age at first coitus. A marker for risky sexual behavior in women. Sex Transm Dis 19 (1992) 331-334
36. Hankins C., Coutlee F., Lapointe N., et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. CMAJ 160 (1999) 185-191
37. Richardson H., Abrahamowicz M., Tellier P.P., et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 14 (2005) 1149-1156
38. Xi L.F., Kiviat N.B., Hildesheim A., et al. Human papillomavirus type 16 and 18 variants: Race-related distribution and persistence. J Natl Cancer Inst 98 (2006) 1045-1052
39. Kjaer S.K., Munk C., Winther J.F., Jorgensen H.O., Meijer C.J., and van den Brule A.J. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 14 (2005) 1528-1533
40. Luostarinen T., Lehtinen M., Bjorge T., et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 40 (2004) 1058-1065
41. Gravitt P.E., and Castle P.E. Chlamydia trachomatis and cervical squamous cell carcinoma. JAMA 285 (2001) 1703-1704 author reply 5-6.
42. Shields T.S., Brinton L.A., Burk R.D., Wang S.S., Weinstein S.J., Ziegler R.G., et al. A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 13 (2004) 1574-1582 Oct.
43. Castle P.E., Hillier S.L., Hildesheim A., et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10 (2001) 1021-1027
44. Kulkarni S., Rader J.S., Zhang F., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7 (2001) 429-434
45. Smith J.S., Munoz N., Herrero R., et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis 185 (2002) 324-331
46. Smith J.S., Bosetti C., Munoz N., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 111 (2004) 431-439
47. Madeleine M.M., Anttila T., Schwartz S.M., et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 120 (2007) 650-655
48. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. International Collaboration of Epidemiological Studies of Cervical Cancer. Int J Cancer 120 (2007) 885-891
49. Franco E.L., Duarte-Franco E., and Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 164 (2001) 1017-1025
50. Konya J., and Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82 (2001) 205-238
51. Franco E.L., and Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 3 (2007) 319-327
52. Centers for Disease Control and Prevention (CDC). http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine.htm Accessed June 25, 2007.
53. Food and Drugs Administration (FDA). http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html Accessed June 25, 2007.